標(biāo)題: Titlebook: Breast Cancer Treatment: An Interdisciplinary Approach; Nima Rezaei Book 2024 The Editor(s) (if applicable) and The Author(s), under exclu [打印本頁] 作者: 淹沒 時間: 2025-3-21 16:19
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach影響因子(影響力)
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach影響因子(影響力)學(xué)科排名
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach網(wǎng)絡(luò)公開度
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach被引頻次
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach被引頻次學(xué)科排名
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach年度引用
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach年度引用學(xué)科排名
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach讀者反饋
書目名稱Breast Cancer Treatment: An Interdisciplinary Approach讀者反饋學(xué)科排名
作者: 館長 時間: 2025-3-21 22:29
Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective,d therapy for TNBC is challenging. Chemotherapy, radiation therapy, and surgical resection are the existing treatment options for TNBC. Chemotherapy is sensitive to TNBC; however, development of resistance mechanisms and recurrence remain the major reasons of treatment failure in patient with TNBC. 作者: Estrogen 時間: 2025-3-22 02:14
Advances in Local Ablative Techniques for Breast Cancer,ant mastectomies, which often led to significant physical and psychological morbidity, the focus has shifted to breast-conserving surgery and minimally invasive ablative techniques..This chapter provides a comprehensive review of the various ablative modalities available for breast cancer management作者: 多產(chǎn)魚 時間: 2025-3-22 07:36 作者: 流利圓滑 時間: 2025-3-22 08:59 作者: podiatrist 時間: 2025-3-22 13:59 作者: Insufficient 時間: 2025-3-22 20:23
Updates on the Management of Ductal Carcinoma In Situ of the Breasts,rement. Adjuvant radiotherapy is usually advised in patients who received lumpectomy. However, over the last decades, de-escalating DCIS treatment has been a debatable topic. Ongoing randomized controlled trials (RCTs) are now in progress to evaluate whether or not we could safely omit surgery in se作者: 預(yù)測 時間: 2025-3-22 21:45
Nanostructured Lipid Carrier as a Strategy for the Treatment of Breast Cancer,of deaths annually worldwide. Conventional treatment, although clinically effective, is associated with the development of resistance in more advanced stages of the disease and high toxicity in healthy cells, leading to a poor prognosis. Furthermore, the active compounds that represent these therape作者: 真繁榮 時間: 2025-3-23 03:22
Managing Breast Cancer Using the Cell-Surface GRP78,tment of breast cancer, there is a need for more effective management strategies..Different avenues emerged recently use the glucose-regulated protein 78 (GRP78) in cancer patients both in diagnosis and in treatment. In addition to managing the unfolded protein response under the stress of the unfol作者: 繁重 時間: 2025-3-23 05:57 作者: Chameleon 時間: 2025-3-23 11:54
Discovering New Targets in Triple-Negative Breast Cancer (TNBC): The Androgen Receptor and the Estr) and the absence of type-2 epidermal growth factor receptor (HER-2) overexpression. This status makes TNBC a challenge for scientists and physicians. Many studies tried to characterize the TNBC to find new targetable proteins to cure this BC subgroup, and the results have certainly underlined its h作者: LITHE 時間: 2025-3-23 15:53 作者: ILEUM 時間: 2025-3-23 19:27 作者: Tremor 時間: 2025-3-24 01:33
Tumor Microenvironment Modulation and Its Impact on Immunotherapy in Triple-Negative Breast Cancer,se due to the lack of specific targetable receptors and its extremely invasive nature makes it a significant point of scientific interest. The tumor microenvironment (TME) in TNBC is a dynamic and diverse landscape composed of various cellular components involving immune cells (macrophages, dendriti作者: Ferritin 時間: 2025-3-24 03:39 作者: 中古 時間: 2025-3-24 09:09 作者: judiciousness 時間: 2025-3-24 11:34 作者: adipose-tissue 時間: 2025-3-24 18:45 作者: Perennial長期的 時間: 2025-3-24 22:56 作者: 壓倒 時間: 2025-3-25 01:10
Konstruktion von Vorhersagekarten,d therapy for TNBC is challenging. Chemotherapy, radiation therapy, and surgical resection are the existing treatment options for TNBC. Chemotherapy is sensitive to TNBC; however, development of resistance mechanisms and recurrence remain the major reasons of treatment failure in patient with TNBC. 作者: Dappled 時間: 2025-3-25 06:12
Konstruktion von Vorhersagekarten,ant mastectomies, which often led to significant physical and psychological morbidity, the focus has shifted to breast-conserving surgery and minimally invasive ablative techniques..This chapter provides a comprehensive review of the various ablative modalities available for breast cancer management作者: SIT 時間: 2025-3-25 09:26
https://doi.org/10.1007/978-3-658-34614-0rgy X-rays, protons, or other unstable particles, in which hyperproliferative cells, such as cancer cells are affected more and therefore more susceptible to radiotherapy compared to normal cells. When treating early-stage breast cancer, radiotherapy can often be given before, during, or after surge作者: bypass 時間: 2025-3-25 13:18
https://doi.org/10.1007/978-3-658-34614-0ving surgery. Axillary surgery adopts the same goal as sentinel lymph node biopsy. Nowadays, surgery is replaced by ablative treatments in selected cases and for specific indications. Ablation techniques are based on the principle of creating acute cellular necrosis in tissue using thermal or electr作者: fatuity 時間: 2025-3-25 16:33
Gemeinsame Variablen in verteilten Systemen,oped and used include targeted therapies and immunotherapies. Targeted therapies and immunotherapies target specific checkpoints in cell growth and metabolism. These include hormone receptor–targeted therapies, HER2-targeted therapies, cell cycle–targeted therapies, and immune checkpoint inhibitors.作者: brother 時間: 2025-3-25 23:10 作者: 特征 時間: 2025-3-26 01:25
Christoph Beierle,Gabriele Kern-Isbernerof deaths annually worldwide. Conventional treatment, although clinically effective, is associated with the development of resistance in more advanced stages of the disease and high toxicity in healthy cells, leading to a poor prognosis. Furthermore, the active compounds that represent these therape作者: 東西 時間: 2025-3-26 07:05 作者: Tractable 時間: 2025-3-26 10:29
Methoden wissensbasierter Systemerted. Then, investigational and clinical findings supporting the relationships between tumor growth and immune evasion and its impact on both HT and IT are examined. Finally, the rationale for an efficacious combination of a novel IT with conventional HT (HIT) in the largest subset of ER+ breast can作者: Magisterial 時間: 2025-3-26 15:08 作者: 挖掘 時間: 2025-3-26 20:53 作者: acrobat 時間: 2025-3-26 20:57
,Wissensbasierte Systeme im überblick, therapy (ET) was the primary approach for HR-positive/HER2-negative advanced breast cancer (ABC). Despite its efficacy, about 20% develop resistance. Biologically directed therapies, including cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), have gained prominence. Understanding ET resistance mech作者: 賭博 時間: 2025-3-27 03:25 作者: 愛好 時間: 2025-3-27 05:20
Logisches Programmieren und Anwortmengen,f epithelial cells. In breast cancer, the expression of claudin 1 is absent or strongly diminished in 76% of triple-negative breast cancer (TNBC). These tumors constitute the most aggressive subtype of breast cancer. They are a heterogeneous group of breast tumors that do not express estrogen recept作者: Trigger-Point 時間: 2025-3-27 12:49 作者: AWRY 時間: 2025-3-27 14:18
,Wissensbasierte Systeme im überblick,s mellitus (T2D) is one of the most common chronic diseases worldwide. There is a positive association between breast cancer and T2D, especially evident for triple-negative breast cancer (TNBC). In this chapter, we discuss current knowledge regarding the effect of T2D-associated characteristics upon作者: LAY 時間: 2025-3-27 17:48
Methoden wissensbasierter Systemebow joint. The patient underwent comprehensive decongestive therapy (CDT), which included skin care to prevent and mitigate pressure injuries, manual lymphatic drainage to facilitate lymphatic flow, intermittent bandaging with pressure to sustain the edema-reducing impact, and integration of traditi作者: 沙發(fā) 時間: 2025-3-27 21:58 作者: Sputum 時間: 2025-3-28 04:23
978-3-031-65829-7The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: hypnogram 時間: 2025-3-28 06:45
Breast Cancer Treatment: An Interdisciplinary Approach978-3-031-65827-3Series ISSN 2731-4561 Series E-ISSN 2731-457X 作者: 討人喜歡 時間: 2025-3-28 13:27
Nima RezaeiDescribes interdisciplinary approaches to breast cancer treatment.Includes a comprehensive coverage of targeted therapy of breast cancer.Contains updated reviews on breast cancer hormone therapy作者: DUST 時間: 2025-3-28 15:55
Interdisciplinary Cancer Researchhttp://image.papertrans.cn/b/image/192759.jpg作者: 他很靈活 時間: 2025-3-28 19:59
2731-4561 a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value to researchers and oncologists who wish to extend their knowledge on breast can978-3-031-65829-7978-3-031-65827-3Series ISSN 2731-4561 Series E-ISSN 2731-457X 作者: 沉著 時間: 2025-3-29 02:31
Advances in Local Ablative Techniques for Breast Cancer,servation and aesthetic outcomes. Moreover, due to the minimally invasive nature, they are particularly beneficial for patients unfit for traditional surgeries, as most of them can be performed without general anesthesia..However, the non-excisional nature of these procedures raises concerns about t作者: Ligneous 時間: 2025-3-29 06:59
Radiotherapy in Breast Cancer,tment plan. The dose of radiation given is split into fractions, usually given daily, over a few days or weeks, depending on the choice of radiotherapy. A combination of chemotherapy or immunotherapy with radiotherapy is recommended for the progressive stages of breast cancer. This chapter dwells on作者: 改變立場 時間: 2025-3-29 07:45 作者: abysmal 時間: 2025-3-29 13:55 作者: MUT 時間: 2025-3-29 19:29
A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer, retrospective 2:1 ratio control-case study where ER+ breast cancer patients who benefited clinically during conventional first-line antiestrogen HT additionally received cyclic interferon beta interleukin-2 sequence, showed superior results to those who received HT alone, and results also were comp作者: 偽造 時間: 2025-3-29 22:25 作者: EVEN 時間: 2025-3-30 02:40
Addressing , Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer, associated with tumor tissue analysis. . mutations, detected in 20–40% of ABC cases undergoing aromatase inhibition, significantly impact prognosis and therapeutic responses. Strategic management of . mutations involves monitoring and adjusting treatment approaches, such as transitioning to fulvest作者: intimate 時間: 2025-3-30 04:53
Tumor Microenvironment Modulation and Its Impact on Immunotherapy in Triple-Negative Breast Cancer,oint inhibitors, monoclonal antibodies, vaccines, and TME modulation have been developed recently to reshape the TME and treat TNBC. Immunomodulatory medications can adjust the TME by suppressing angiogenesis, promoting infiltration of immune cells, blocking T regulatory cells, and boosting the effi作者: ARENA 時間: 2025-3-30 12:10
Claudin 1: An Emerging Target for Triple-Negative Breast Cancer, to treat these tumors lacking efficient therapies. Clinical studies reported that a loss of claudin 1 expression correlates with increased aggressiveness and metastasis potential associated with recurrence of disease in invasive breast carcinoma patients. Although the role of claudin 1 in breast ca作者: medium 時間: 2025-3-30 14:29 作者: AIL 時間: 2025-3-30 16:52 作者: 燒瓶 時間: 2025-3-30 22:37 作者: white-matter 時間: 2025-3-31 01:28 作者: 呼吸 時間: 2025-3-31 08:20 作者: Meander 時間: 2025-3-31 11:51
https://doi.org/10.1007/978-3-658-34614-0tment plan. The dose of radiation given is split into fractions, usually given daily, over a few days or weeks, depending on the choice of radiotherapy. A combination of chemotherapy or immunotherapy with radiotherapy is recommended for the progressive stages of breast cancer. This chapter dwells on作者: Cholagogue 時間: 2025-3-31 14:28 作者: Yourself 時間: 2025-3-31 19:20
Reproduzierbarkeit verteilter Simulation,d low-risk DCIS patients. However, apart from oncologic outcomes, the patient’s acceptance and the psychosocial impact of conservative treatment for DCIS should be taken into consideration in the treatment planning for DCIS..The importance of oncologic safety is obvious in decision-making, but to pa作者: 暫時別動 時間: 2025-4-1 00:03
Methoden wissensbasierter Systeme retrospective 2:1 ratio control-case study where ER+ breast cancer patients who benefited clinically during conventional first-line antiestrogen HT additionally received cyclic interferon beta interleukin-2 sequence, showed superior results to those who received HT alone, and results also were comp作者: 罐里有戒指 時間: 2025-4-1 04:12
Methoden wissensbasierter Systemether weakness of TNBC is the presence of a lot of immune cells such as tumor-infiltrating lymphocytes. This makes immunotherapy another fascinating weapon to treat this incurable cancer..To date, many studies have been focused on other two steroid receptors belonging to the nuclear receptor superfam作者: 坦白 時間: 2025-4-1 09:06
,Wissensbasierte Systeme im überblick, associated with tumor tissue analysis. . mutations, detected in 20–40% of ABC cases undergoing aromatase inhibition, significantly impact prognosis and therapeutic responses. Strategic management of . mutations involves monitoring and adjusting treatment approaches, such as transitioning to fulvest作者: 愉快么 時間: 2025-4-1 14:11 作者: AXIS 時間: 2025-4-1 15:02
Logisches Programmieren und Anwortmengen, to treat these tumors lacking efficient therapies. Clinical studies reported that a loss of claudin 1 expression correlates with increased aggressiveness and metastasis potential associated with recurrence of disease in invasive breast carcinoma patients. Although the role of claudin 1 in breast ca
